All Major Solid Tumors

Cancer Type

Tumor Tissue (FFPE)

Specimen Requirements

10 Working Days

Turnaround Time ¹

ACTOnco®+ analyzes >400 genes and 13 fusion genes to assist physicians identify the most suitable therapies. Treatment evaluations include targeted therapy, immunotherapy, hormone therapy, and chemotherapy.

Comprehensive Cancer Genomic Profiling Service


Specially Curated Genes


Fusion Genes


Fusion Transcripts

Hallmarks of ACTOnco®+

Comprehensive Pathway-Based Panel

Sequences 440 cancer-related genes,13 fusion genes and more than 350 fusion transcripts covering most key cancer signaling pathways for targeted therapy.

Predicts Immunotherapy Response

Incorporates tumor mutationalburden, immune-related gene information and MSI status for a more accurate immunotherapy recommendation.

Provides Pharmacogenetics Information

Predicts response to treatment by identifying inherited genetic variations (polymorphisms). Pharmacogenetics information can be used to match patients with the treatment that is most effective, while minimizing potential side-effects.

Short Turnaround Time

Provides professional solutions within 10 working days (from the date of receipt of approved samples at our CAP-accredited laboratory).

Pioneering Bioinformatics

Integrates cancer biology, medical biology, molecular biology, cell biology, immunology, bioinformatics, data science and pharmaceutical biology to provide insightful interpretation of the data analyses.

Report Consultation

Complements every report with a face-to-face consultation with an expert from our medical team.

High Sensitivity

Uses Next-generation Sequencing (NGS) for microscale specimens


Find the Right Treatment for Your Cancer Patient

ACTOnco®+ aims to support and answer the clinical challenges faced during the management of major solid tumors. The ACTOnco®+ panel comprises 440 specially curated genes, 13 fusion genes and more than 350 fusion transcripts, and references the hallmarks of cancer to recommend treatment strategies, including chemotherapy, targeted therapy, immunotherapy and pharmacogenomics.

Cancer Signaling Pathway Analysis: Identify More Treatment Options Through Pathway Integration

ACTOnco®+ comprehensively identifies genetic alterations of each signaling pathway to evaluate drug options based on upstream and downstream interactions. By incorporating comprehensive genomics profiling and integrating signaling pathway analysis, ACTOnco®+ provides clinicians with a more holistic understanding of the major cancer-driven events during tumorigenesis to nominate more targeted therapeutic strategies.

Extensive-Range of Cancer Types

  • All solid tumors

Suitable for Most Patients

  • Newly diagnosed patients with complex cancer type
  • Recurrent and metastatic cases
  • Patients searching for treatment (and trials) options
  • Diagnosed with advanced cancer or late-stage cancer

Provides Pharmacogenetics Information

  • Genetic alterations, including BRCA1/2
  • Therapeutic implications for FDA-approved chemotherapy, hormonal therapy, targeted therapy, PARP1 inhibitors and immunotherapy drugs, and other drugs used in clinical trials
  • Prediction of immunotherapy response, including TMB and MSI status
  • Pharmacogenomics information

Technical Specifications

Next Generation Sequencing

440 cancer-related genes

Specimen Requirements2

Tumor tissue (FFPE)

Target Region

> 1,000,000 bps

Sequencing Mean Depth

≥ 500 X


Comprehensive testing of 13 fusion genes and more than 350 fusion transcripts

Prediction of Immunotherapy Response

Tumor mutational burden (TMB)
Microsatellite instability (MSI) testing



Disclaimers / Footnotes

  1. Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.
  2. Please refer to our specimen instructions.

Book a Test

Explore the immense possibilities and promising future of precision medicine. Together, let us unlock the power of genomic testing and personalize cancer care for the most effective treatment.

Get Started